March 9, 2026

Background

Brian Rifkin

Is REACT (Renal Autologous Cell Therapy) the ...

This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.

February 23, 2026

Background

Brian Rifkin

2026 KDIGO Anemia Management Guidelines

This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease

February 8, 2026

Background

Cristina Adriana Popa

To INFINITI and Beyond: SGLT2 Inhibitors in ...

This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

January 26, 2026

Background

Cristina Adriana Popa

POTCAST- K+ Pop and Arrhythmia Drop

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

January 11, 2026

Background

Brian Rifkin

A VALIANT effort to combat complement disorders ...

This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.

liver

swapnil hiremath

April 5, 2021

Commentary

The Trials and Tribulations of Terlipressin

swapnil hiremath

April 5, 2021

Commentary

The Trials and Tribulations of Terlipressin

Elliot Tapper, Director of the Michigan Cirrhosis program and creator of several liver tweetorials, gives us his thoughts on the CONFIRM trial and where we go from here.

swapnil hiremath

April 5, 2021

Background

Terlipressin and Hepatorenal Syndrome: Winning the Battle and Losing the War?

swapnil hiremath

April 5, 2021

Background

Terlipressin and Hepatorenal Syndrome: Winning the Battle and Losing the War?

This week, we will discuss the CONFIRM trial. It was supposed to confirm the role of terlipressin in reversing hepatorenal syndrome…unfortunately it hit the nephrology nihilism wall.